LifeCycle Pharma Passing of Extraordinary General Meeting - Change of Company Name to Veloxis Pharmaceuticals A/S and Election of New Board Member

HORSHOLM, Denmark, July 7, 2011 /PRNewswire/ --

Summary: At the Extraordinary General Meeting held earlier today all proposals made by the Board of Directors were adopted.

At the general meeting, Ed Penhoet was elected as new member of the Board of Directors for a period ending at the next Annual General Meeting of the company.

The Board of Directors will hereafter comprise:

Kim Bjornstrup (Chairman)
Thomas Dyrberg (Deputy Chairman)
Kurt Anker Nielsen
Anders Gotzsche
Mette Kirstine Agger
Ed Penhoet

The proposal made by the Board of Directors to change the name of the company from LifeCyclePharma A/S to Veloxis Pharmaceuticals A/S and to amend the Articles of Association accordingly was approved. LifeCyclePharma A/S shall hereafter be the company's secondary name.

The proposal made by the Board of Directors to amend the Articles of Association Article 11 in accordance with the previous resolution to use electronic communication was adopted.

The chairman of the meeting was, with a right of substitution, authorized to register resolutions passed by the general meeting with the Danish Commerce and Companies Agency and to make such alterations as the Agency may require for registration or approval.

For more information, please contact:

Veloxis Pharmaceuticals A/S

John Weinberg, M.D.

SVP, Commercial Operations & Investor Relations

Phone: +1 908 304 3389


Anja Leschly

VP, Human Resources and Communication

Phone: + 45 2055 3818


About Veloxis Pharmaceuticals

Veloxis is a specialty pharmaceutical company. Clinical development is the core of our efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDoseĀ®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, FenoglideĀ®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit

SOURCE Veloxis Pharmaceuticals A/S

Back to news